Led by Assistant Professor of Quantum Sensing Dominik Bucher, the QTAS team, notably Robin D. Allert(MSc), Dr. Linyan Nie, Karl D. Briegel (MSc), and Nick R. von Grafenstein (MSc), was recognized for their work on the development of an innovative liquid biopsy method as a tool in cancer monitoring. Currently, therapeutic effects are generally analyzed only after 3-to-6-month intervals, thereby possibly delaying any necessary changes to the treatment, resulting in suboptimal therapeutic results. QTAS, with collaborators at Ludwig Maximilian University of Munich Hospital, aims to significantly reduce the observation interval and to allow high-precision identification of individual cancer cells. The Medical Valley Award will be used to validate this technology in whole blood samples, thus paving the way to a new era of cancer monitoring and precision medicine.
Further information
Prof. Dominik Bucher (Assistant Professorship of Quantum Sensing)
Medical Valley Award information (in German)
Munich Center for Quantum Science & Technology https://www.mcqst.de/news-and-events/news/quantum-sensor-technology-for-cancer-monitoring-wins-medical-valley-award.html
Munich Quantum Valley news item: https://www.munich-quantum-valley.de/news-events/detail/quantum-sensor-technology-for-cancer-monitoring-wins-medical-valley-award
News from Medical Valley EMN https://www.medical-valley-emn.de/bericht-quantensensor-technologie-fuer-das-krebs-monitoring-wird-mit-dem-medical-valley-award-ausgezeichnet/ (in German)
Press contact